Correction of Anemia in Patients With Renal Pathology in Pregravidal Рreparing

The studies have shown that the major pathogenetic factor in the development of anemia was an absolute deficiency of erythropoietin, which was observed in 46.6% of patients with chronic kidney disease stage 1, 58.1% - with chronic kidney disease stage 2 and 61.7% - with chronic kidney disease stage 3. Relative increase in the level of EPO at reduced Hb was greatest in patients with chronic kidney disease stage 1 and the lowest in patients with chronic kidney disease stage 3. Normochromic normocytic anemia was characteristic for most patients with renal disease. Increased serum concentrations of pro-inflammatory cytokines were observed in the majority of patients with anemia (Il-1β - in 86.3%, Il- 6 – in 70.5 % of cases). Comprehensive treatment with recombinant human erythropoietin and iron allowed to reach the target Hb values in 94.1 % of patients with anemia , while a negative association was detected between the level of endogenous erythropoietin and Hb percentage growth during the treatment period. Antianemic therapy led to a statistically significant decrease in serum concentrations of Il-1β and Il- 6 cytokines.